Similarly, categorization of T2DM + HTN and CAD + T2DM + HTN patients by short-term SGLT2 inhibitor use demonstrated 0.726-fold lower MRV(Venular)C in users than non-users (P < 0.001, 95% CI: 0.656–0.803) with concurrent MRV(Venular)C reductions at 0.5–1.0PD (OR = 0.947), 1.0–1.5PD (OR = 0.924), 1.5–2.0PD (OR = 0.901), and 2.0–2.5PD (OR = 0.942) (all P < 0.001; 95% CIs: 0.923–0.971, 0.894–0.955, 0.866–0.938, 0.916–0.970 respectively). Here, SLC5A2 is linked to type 2 diabetes mellitus.